Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | CCND2 | P30279 | 1/20 | 0.39 |
| ▸ | CCND3 | P30281 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.38 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.38 |
| ▸ | NOD2 | Q9HC29 | 3/20 | 0.38 |
| ▸ | USP2 | O75604 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 4/20 | 0.38 |
| ▸ | SRC | P12931 | 4/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12671535 | 0.87 | CDK4 (0.41) | CDK4CCND1CCND2CCND3FGFR1 | |
| SCHEMBL13252021 | 0.84 | CDK4 (0.42) | CDK4CCND1CCND2CCND3FGFR1 | |
| SCHEMBL13252101 | 0.81 | CDK4 (0.43) | CDK4CCND1CCND2CCND3FGFR1 | |
| SCHEMBL12671536 | 0.81 | CDK4 (0.43) | CDK4CCND1CCND2CCND3FGFR1 | |
| SCHEMBL13225903 | 0.80 | BRAF (0.41) | BRAF | |
| SCHEMBL13225905 | 0.75 | BRAF (0.41) | BRAF | |
| SCHEMBL12671174 | 0.75 | BRAF (0.45) | BRAF | |
| SCHEMBL13225923 | 0.67 | MAP4K1 (0.41) | — | |
| SCHEMBL13225922 | 0.67 | MAP4K1 (0.39) | FGFR4 | |
| SCHEMBL1570948 | 0.66 | BRAF (0.50) | PDGFRBPDGFRAABL1BRAFMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008079988-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2011-05-12 | — | — | WO | disclosed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
| WO-2009153313-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| WO-2008079988-A2 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | CDK4 26/4885CCND1 641/4885CCND2 798/4885 |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | CDK4 6/4885CCND1 333/4885CCND2 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.